Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)

BACKGROUND: Androgen deprivation therapy (ADT) for prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonists can be improved. OBJECTIVE: To assess safety, the frequency and severity of hot flushes (HFs), bone health, and antitumor effects of high-dose estetrol (HDE4) when combined w...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur Urol Open Sci
Autors principals: Coelingh Bennink, Herjan J.T., van Moorselaar, Jeroen A., Crawford, E. David, Roos, Erik P.M., Somford, Diederik M., Roeleveld, Ton A., de Haan, Tjard D., van Melick, Harm H.E., Reisman, Yacov, Zimmerman, Yvette, van Osta, Gonnie, Krijgh, Jan, Shore, Neal D., Saad, Fred, Schally, Andrew V., Debruyne, Frans M.J.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2021
Matèries:
Prostate Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8317802/
https://ncbi.nlm.nih.gov/pubmed/34337526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.euros.2021.04.005
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars